Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sancho-Saldaña, Agustín, Gil Sánchez, Anna, Quirant-Sánchez, Bibiana, Nogueras, Lara, Peralta, Silvia, Solana, Maria José, González-Mingot, Cristina, Gallego, Yhovanni, Quibus, Laura, Ramo-Tello, Cristina, Presas-Rodríguez, Silvia, Martínez-Cáceres, Eva, Torres, Pascual, Hervás, José Vicente, Valls, Joan, Brieva, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/
https://www.ncbi.nlm.nih.gov/pubmed/35566632
http://dx.doi.org/10.3390/jcm11092509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099725/
https://www.ncbi.nlm.nih.gov/pubmed/35566632
http://dx.doi.org/10.3390/jcm11092509

Ejemplares similares